- Home
- CLGN vs LNAI Comparison
CLGN vs LNAI Comparison
Compare CLGN & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- LNAI
- Stock Information
- Founded
- CLGN 2004
- LNAI N/A
- Country
- CLGN Israel
- LNAI United States
- Employees
- CLGN N/A
- LNAI N/A
- Industry
- CLGN Industrial Specialties
- LNAI Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- LNAI Health Care
- Exchange
- CLGN Nasdaq
- LNAI Nasdaq
- Market Cap
- CLGN 33.8M
- LNAI 29.9M
- IPO Year
- CLGN N/A
- LNAI N/A
- Fundamental
- Price
- CLGN N/A
- LNAI $1.24
- Analyst Decision
- CLGN Strong Buy
- LNAI
- Analyst Count
- CLGN 2
- LNAI 0
- Target Price
- CLGN $11.50
- LNAI N/A
- AVG Volume (30 Days)
- CLGN 257.5K
- LNAI 486.0K
- Earning Date
- CLGN 11-26-2025
- LNAI 11-13-2025
- Dividend Yield
- CLGN N/A
- LNAI N/A
- EPS Growth
- CLGN N/A
- LNAI N/A
- EPS
- CLGN N/A
- LNAI N/A
- Revenue
- CLGN $2,402,000.00
- LNAI N/A
- Revenue This Year
- CLGN $1,617.28
- LNAI N/A
- Revenue Next Year
- CLGN $83.54
- LNAI N/A
- P/E Ratio
- CLGN N/A
- LNAI N/A
- Revenue Growth
- CLGN 248.62
- LNAI N/A
- 52 Week Low
- CLGN $1.31
- LNAI $1.11
- 52 Week High
- CLGN $4.99
- LNAI $21.00
- Technical
- Relative Strength Index (RSI)
- CLGN 45.87
- LNAI N/A
- Support Level
- CLGN $2.11
- LNAI N/A
- Resistance Level
- CLGN $2.44
- LNAI N/A
- Average True Range (ATR)
- CLGN 0.22
- LNAI 0.00
- MACD
- CLGN -0.03
- LNAI 0.00
- Stochastic Oscillator
- CLGN 23.36
- LNAI 0.00
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.